Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 13600
JPY 46800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(250)

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NEjMUGNEgXSxdH;4bYMhSXO|YYm= MVO1NEDPxE1? MVu0PEBp NIj3fpZFVVOR NFvRPW1McWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm MnG2NVA1QTl4NEO=
OVCA 429 NIfx[YdHfW6ldHnvckBCe3OjeR?= MYGzNFAhdk1? M1zJUFQ5KGh? MWTEUXNQ MkLzSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz MkfWNVA6QTl5Nk[=
RPMI8226 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rMdFExOCCwTR?= NECweJg1QCCq MYLEUXNQ M4HyXmlEPTB;M{Cgcm0> MoDMNVE{ODZ2OEm=
Dox40 NUPiSZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LKRVExOCCwTR?= MXO0PEBp MoLkSG1UVw>? M4Sxb2lEPTB;NECgcm0> NGXtW3MyOTNyNkS4PS=>
MR20 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNFAhdk1? NUj3N5l7PDhiaB?= NUPMOIdkTE2VTx?= NFvuZ5ZKSzVyPUKwJI5O NYLxdpVROTF|ME[0PFk>
LR5 NGPmfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLaV41qOTByIH7N MlzzOFghcA>? M{\WTGROW09? MlfyTWM2OD1{MDDuUS=> NXHsdVI5OTF|ME[0PFk>
U266 NVfMe3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonENVAxKG6P NF;nZ|A1QCCq NYrXbYdUTE2VTx?= MVHJR|UxRTNibl2= NF3RSlcyOTNyNkS4PS=>
IM-9 M3LaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\RN3YyODBibl2= NFXEXpI1QCCq NHjFbJlFVVOR NHrObnRKSzVyPU[gcm0> Mn\3NVE{ODZ2OEm=
Hs Sultan NEeyeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNFAhdk1? NFH0WmU1QCCq NVX3N2g3TE2VTx?= MlPnTWM2OD1{MDDuUS=> NGPUd3cyOTNyNkS4PS=>
PAM-LY2 M2mxRWZ2dmO2aX;uJGF{e2G7 MoX0NVAxKG6P NIT1PWoyOiCq M1vGdmROW09? MVjJcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?= NXSy[FcxOTF|NUC5NVM>
PAM 212 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nEPVExOCCwTR?= NXzjc|FqPzJiaB?= NXzxV5M2TE2VTx?= NVrObJBWUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M13rTlEyOzVyOUGz
PAM-LY2 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\IfVExOCCwTR?= NWXsNFVCPzJiaB?= MmTxSG1UVw>? NFrp[XVKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NH7EUpQyOTN3MEmxNy=>
B4B8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEToOGEyODBibl2= NGm3Zow4OiCq NYLqRnFGTE2VTx?= MWfJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MoXHNVE{PTB7MUO=
B7E3 M3q1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNFAhdk1? NH:0eWI4OiCq MVXEUXNQ NW\EUWkyUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MkfCNVE{PTB7MUO=
UM-SCC-9 NGPaT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPoWph7OTByIH7N NYqwOJFtPzJiaB?= NH7Jcm1FVVOR NF\iOndKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NYnLepNMOTF|NUC5NVM>
UM-SCC-11B M3LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDzNVAxKG6P MX23NkBp NFzlZnhFVVOR NHfYO2pKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MljHNVE{PTB7MUO=
H460 NF3COVNHfW6ldHnvckBCe3OjeR?= NGrFdlMyOCEQvF2= NE\aZmMzPCCq MX3EUXNQ NWfBT|hyUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= M2f6dFEzPDl{MUG3
U266 NUPnTIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi4dWREPTByIH7nM41t NGTrNYQ1QCCq MkXQSG1UVw>? NGXVWFFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHnY[2YyOjZ|MU[xPS=>
ARH77 NXKz[2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:4O3E2ODBibnevcYw> M375SVQ5KGh? MUjEUXNQ NFfB[YZKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MWixNlY{OTZzOR?=
WAD-1 NIDu[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK1NFAhdmdxbXy= M1;v[|Q5KGh? MX3EUXNQ NVvKSoc5UW6qaXLpeJMh[2WubDDndo94fGh? Ml7JNVI3OzF4MUm=
U266/LR7 NVT3bVU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nyc|UxOCCwZz;tcC=> M160clQ5KGh? NUXCSW1ETE2VTx?= MnvyTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M{\WfVEzPjNzNkG5
U266/dox4 M1\sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzkbmg2ODBibnevcYw> NWThZ2lnPDhiaB?= NHnCcGFFVVOR NYHRUYdYUW6qaXLpeJMh[2WubDDndo94fGh? MlztNVI3OzF4MUm=
RPMI8226/LR5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjzZmFRPTByIH7nM41t MoXLOFghcA>? MWXEUXNQ MVXJcohq[mm2czDj[YxtKGe{b4f0bC=> NEnIUmYyOjZ|MU[xPS=>
H460 NG\yc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHpNVAh|ryP MorMO|IhcA>? M1;qeGROW09? M2jNUmlEPTB;MUCwJI5O NYH2PIdOOTJ4M{G2NlA>
H358 NIfQVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvnZoMyOCEQvF2= M{fFXFczKGh? NWPkUJo{TE2VTx?= NUTHfYo4UUN3ME23NEBvVQ>? NHu3ZocyOjZ|MU[yNC=>
H322 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV61TY9YOTBizszN MkK2O|IhcA>? MXjEUXNQ MlfITWM2OD14MkCgcm0> NF7xNW8yOjZ|MU[yNC=>
H460 Mn;mSpVv[3Srb36gRZN{[Xl? NGTvSlYyODBibl2= M2\NW|I1KGh? NGnybGtFVVOR M1[5cWlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? M4DlNVEzPjNzNkKw
LNCap-Pro5 M3O4[GZ2dmO2aX;uJGF{e2G7 MUCxJO69VQ>? NVT4WYNDPCCq MoD1SG1UVw>? MmTDV5Ri[mmuaYrld{BxPTN? NETBeHkyPDZzMkWzNi=>
T29 NH7NVHBCeG:ydH;zbZMhSXO|YYm= M2nnS|UxKG6P MXO0PEBpKA>? MmDZSG1UVw>? MXTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{TzO|E3Pzd6MUe5
T29Kt1 NFzwUFRCeG:ydH;zbZMhSXO|YYm= MmnQOVAhdk1? MnfqOFghcCB? M3L0bmROW09? NXjzZpI2UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NX\weotCOTZ5N{ixO|k>
HCT116 NHGybIhCeG:ydH;zbZMhSXO|YYm= NULVbJQ{PTBibl2= Ml;UOFghcCB? NGPmeoNFVVOR NFjDRYVKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{\ueVE3Pzd6MUe5
HKe-3 MkX1RZBweHSxc3nzJGF{e2G7 MV61NEBvVQ>? M3fpN|Q5KGhi M3rHe2ROW09? NVnxOGpCUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUjYfI5WOTZ5N{ixO|k>
NB-1691 NUKzdI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPiRYNWOSEQvF2= M2DReFczKGh? NGjRRVJKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= M4\6NlE4Pjh7Nki0
CHLA-255 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxJO69VQ>? MoPoO|IhcA>? M1z5N2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= M1n1OVE4Pjh7Nki0
SK-N-AS NF3XOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln6NUDPxE1? NIK3THU4OiCq NWLzfo9uUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> MVyxO|Y5QTZ6NB?=
NB-1691 NXrxU5hoTnWwY4Tpc44hSXO|YYm= Mlr5NVAhdk1? M3myNlI1KGh? MnHsV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> MmrxNVc3QDl4OES=
CHLA-255 NHjacZlHfW6ldHnvckBCe3OjeR?= MXWxNEBvVQ>? NH7NSGwzPCCq MoPIUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MU[xO|Y5QTZ6NB?=
RPMI 8226 NW\I[5dRTnWwY4Tpc44hSXO|YYm= M2DqXlIxKG6P Mlv3PEBp M4nzNnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NHT2[ngyQTR|NkC1NC=>
MM.1S NVjz[nJwTnWwY4Tpc44hSXO|YYm= MYiyNEBvVQ>? MYC4JIg> MnG3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MYKxPVQ{PjB3MB?=
U266 NWnhTFVwTnWwY4Tpc44hSXO|YYm= MWKyNEBvVQ>? Mk\1PEBp MX3TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MVSxPVQ{PjB3MB?=
OPM1 NVT5WnFKTnWwY4Tpc44hSXO|YYm= MnLkNlAhdk1? NGLxVm85KGh? M3jSN3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M2nV[VE6PDN4MEWw
INA6 NGOyVphHfW6ldHnvckBCe3OjeR?= Mo\vNlAhdk1? NH;Pb4Y5KGh? NILJZodUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NIPmWnoyQTR|NkC1NC=>
OPM2 NETYdW9HfW6ldHnvckBCe3OjeR?= MlHVNlAhdk1? NYfGcJN2QCCq MWXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M3vESVE6PDN4MEWw
RPMI 8226 M4\HVWZ2dmO2aX;uJGF{e2G7 NXPCRVBsOjBibl2= M4jqUVghcA>? NHHs[FNKdmS3Y3XzJGRPSSC|eX70bIV{cXN? MoDuNVk1OzZyNUC=
BaF/3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlqwNVAxKG6P NX;RSmhuPDhiaB?= MUTJR|UxRTZwMjDuUS=> NGHsZ4gzODNyNU[5Ni=>
BaF/3-p210 NGjPNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofxNVAxKG6P MmryOFghcA>? NH;qXI9KSzVyPUSuO{BvVQ>? NWSz[2dXOjB|MEW2PVI>
TCC-S MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\mSVExOCCwTR?= NFu2cZk1QCCq M3:4SGlEPTB;Mj64JI5O MV2yNFMxPTZ7Mh?=
BaF/3 M37nRmZ2dmO2aX;uJGF{e2G7 MY[2JI5O NFn3bYc1QCCq NFS3coFKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NVe1XYg2OjB|MEW2PVI>
BaF/3-p210 NUjWW|B1TnWwY4Tpc44hSXO|YYm= NH\PXpE3KG6P M3nNclQ5KGh? M2\XPWlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> Mn7hNlA{ODV4OUK=
BaF/3-p210 NWD2SWU{TnWwY4Tpc44hSXO|YYm= MkDMOkBvVQ>? MUCyOEBp M3jBenJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk MoH5NlA{ODV4OUK=
Raji MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ew[FEh|ryP NY[3TGYzOjRiaB?= M3;ZS3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M3\HT|IyOTdyOUi4
LCL-1 NUPLRVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPDfZlCOSEQvF2= MWSyOEBp M{LMW3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= Mnf2NlEyPzB7OEi=
LCL-2 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTnNUDPxE1? M1jy[|I1KGh? NVvae4RLWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NXfheJNyOjFzN{C5PFg>
BJAB M2\CVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7qZZYyKM7:TR?= NVzxdFdDOjRiaB?= NVHtclZoWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NUHMVZp[OjFzN{C5PFg>
SNT-13 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXHO4EyKM7:TR?= MVKyOEBp MoXXVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NIm1SXEzOTF5MEm4PC=>
SNT-16 NX7ESVVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\GU4UyKM7:TR?= M3TZblI1KGh? NWDve|FtWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MWKyNVE4ODl6OB?=
Jurkat MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnNVEh|ryP NV:zfYNKOjRiaB?= M1q0OnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M2DoT|IyOTdyOUi4
KAI-3 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPEeJUyKM7:TR?= M2jSW|I1KGh? NHf0N|ZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NEnhXoMzOTF5MEm4PC=>
SNK-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHThVIEyKM7:TR?= NVuyWok5OjRiaB?= MmnwVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi Mk\RNlEyPzB7OEi=
KHYG-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HQRVEh|ryP NYPK[2ZwOjRiaB?= NUf0XVNYWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NIq3NlMzOTF5MEm4PC=>
SNT-16 NEPkd|RCeG:ydH;zbZMhSXO|YYm= NE\yW3UyKM7:TR?= MmXWOkBp M3rGNGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NX;Te|N1OjFzN{C5PFg>
Jurkat NUX1SJQxSXCxcITvd4l{KEG|c3H5 M2eyOVEh|ryP M4jLSFYhcA>? MUTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVuyNVE4ODl6OB?=
KAI-3 MVvBdI9xfG:|aYOgRZN{[Xl? MWmxJO69VQ>? NH3vWlE3KGh? MXXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mk\WNlEyPzB7OEi=
KHYG-1 M3XVOWFxd3C2b4Ppd{BCe3OjeR?= MoTzNUDPxE1? MoezOkBp M1fTc2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NF\JeVczOTF5MEm4PC=>
SNT-13 M3;MO2FvfGm4aYLhcEBCe3OjeR?= NX:0R4NFOSEQvF2= NFK1d40zPCCq MoLpTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MofQNlEyPzB7OEi=
SNT-16 M1nMSGFvfGm4aYLhcEBCe3OjeR?= NX74PWF[OSEQvF2= NFPTPYIzPCCq NHS3NIlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NGLKW4czOTF5MEm4PC=>
KAI-3 NWLQVYVESW62aY\pdoFtKEG|c3H5 MlzZNUDPxE1? MU[yOEBp NF23Ro9KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NFX5S3AzOTF5MEm4PC=>
SNK-6 MXjBcpRqfmm{YXygRZN{[Xl? M{PyNVEh|ryP M1TOZVI1KGh? MWTJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NIXSfZczOTF5MEm4PC=>
RAW 264.7 M{D5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLlNVAxKG6P NFjFVZA1QCCq M{XDS3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXeyNlQzPzF3NB?=
A375 MkSxRZBweHSxc3nzJGF{e2G7 Ml\SNVAhdk1? M4f2UlI1KGh? NXjNRXJsUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHjOfVEzOzB5OUC4Ny=>
BLM M4PDUmFxd3C2b4Ppd{BCe3OjeR?= NYfrd3hYOTBibl2= NUP1elNrOjRiaB?= M1S2dmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MljpNlMxPzlyOEO=
A375 M3zXSmF2fG:yaHHnfUBCe3OjeR?= M33n[VExKG6P M{THPVEzKGh? NX;ERlhqUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MXuyN|A4QTB6Mx?=
BLM MX\BeZRweGijZ4mgRZN{[Xl? M3\tc|ExKG6P MXuxNkBp Mo[yTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MofqNlMxPzlyOEO=
H1299 M13zc2Fxd3C2b4Ppd{BCe3OjeR?= MnS1PFAhdk1? MX[yOEBp MXfEUXNQ NGLtfIZU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= NHPDSoozPTN{M{[5Ny=>
Hut-78 MnHlSpVv[3Srb36gRZN{[Xl? M16xelExOCCwTR?= MXmyOEBp NF62ZXpFVVOR Mor3SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MlLKNlU3QDF|M{W=
H9 NYC3UIxnTnWwY4Tpc44hSXO|YYm= MoXnNVAxKG6P MVOyOEBp M4fq[2ROW09? NWXRT2tOTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u NIrWdo8zPTZ6MUOzOS=>
HH NGD4OllHfW6ldHnvckBCe3OjeR?= M1TUUFExOCCwTR?= M1T2[FI1KGh? NEXvPItFVVOR NVvCOYk4\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u M4LD[lI2PjhzM{O1
Hut-78 MYjNbYdz[XSrb36gRZN{[Xl? M4fibVExOCCwTR?= NEXidZUzPCCq MYDEUXNQ MVzS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn MWOyOVY5OTN|NR?=
HH M4KzbW1q\3KjdHnvckBCe3OjeR?= M1rlRlExOCCwTR?= MlKzNlQhcA>? NF7EdJRFVVOR NH7uRpRT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl NX3RVZFFOjV4OEGzN|U>
U937 NXXISpRtTnWwY4Tpc44hSXO|YYm= M1L5V|ExOCCwTR?= NXrneoN3PiCq MnnkTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NIrISJczPTd7MUS3Oy=>
human PBMC NGD3fHNHfW6ldHnvckBCe3OjeR?= NEHpXlQyODBibl2= NFq2TGQzPCCq NVH1R4pPUW6mdXPld{BKVC16IILlcIVie2V? Mm\6NlU4QTF2N{e=
ES6 M{PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXrdWdKSzVyPUCuNFAzOSCwTR?= MkjUV2FPT0WU
SK-UT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1yLkG2N{BvVQ>? NUjUR4twW0GQR1XS
SH-4 M2HsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\STWM2OD1yLkG3N{BvVQ>? NXL1N3YyW0GQR1XS
TE-9 NF7tdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HUWmlEPTB;MD6xPFIhdk1? NGT3XHJUSU6JRWK=
A253 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULqb3NHUUN3ME2wMlIxQCCwTR?= MnSyV2FPT0WU
no-10 NUHod4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S5V2lEPTB;MD6yNUBvVQ>? NUf2WlBtW0GQR1XS
MMAC-SF NFTjXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonGTWM2OD1yLkKxOkBvVQ>? M2fTUnNCVkeHUh?=
A101D NY\5cXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMkK1JI5O NEDrV4pUSU6JRWK=
NTERA-S-cl-D1 NWnFfFExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr5R4x5UUN3ME2wMlI1OyCwTR?= NHyzepdUSU6JRWK=
8-MG-BA M13Xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPWTWM2OD1yLkK1JI5O NX;qW3lKW0GQR1XS
KNS-42 NVWyN5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfvTWM2OD1yLkK1PEBvVQ>? NVTGOINrW0GQR1XS
LXF-289 NVnCOmZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMk[5JI5O NYHabZJIW0GQR1XS
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrScFNKSzVyPUCuNlg6KG6P NFL6[|NUSU6JRWK=
LOUCY M3zXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzZcW13UUN3ME2wMlI6OyCwTR?= MkfJV2FPT0WU
BB65-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4TWM2OD1yLkOwOEBvVQ>? NYnufJFXW0GQR1XS
D-542MG Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPi[ndpUUN3ME2wMlMzQSCwTR?= NF70R5BUSU6JRWK=
ONS-76 M{jQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorzTWM2OD1yLkOzJI5O M1f4XHNCVkeHUh?=
BB30-HNC NV;COotjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LjV2lEPTB;MD6zN|Uhdk1? NHzIPGhUSU6JRWK=
KS-1 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUTWM2OD1yLkO0JI5O NWfhW4QxW0GQR1XS
A388 M3jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwM{W2JI5O NX\hWFN4W0GQR1XS
ES8 NGTPcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17GVGlEPTB;MD60JI5O NV;jUJNwW0GQR1XS
MZ2-MEL NIWzcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnzR2NKSzVyPUCuOFA4KG6P MVTTRW5ITVJ?
HCC2998 M4Ht[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjJVVRTUUN3ME2wMlQyOiCwTR?= NWPqUGFiW0GQR1XS
D-247MG NI\wUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[1cGlEPTB;MD60NVMhdk1? MlTQV2FPT0WU
ACN MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D1SWlEPTB;MD60NVchdk1? M3nhVHNCVkeHUh?=
LB2518-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2exNmlEPTB;MD60NlUhdk1? NEfHWnhUSU6JRWK=
ES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjsTWM2OD1yLkSzJI5O MnLyV2FPT0WU
HCE-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn0VmRKSzVyPUCuOFM6KG6P MYTTRW5ITVJ?
OS-RC-2 NIjMcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHHc4pKSzVyPUCuOFQhdk1? NULvOIlqW0GQR1XS
MFH-ino Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD1yLkS0N{BvVQ>? NFXtfm9USU6JRWK=
OCUB-M Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPIXYxKSzVyPUCuOFQ4KG6P M1z5N3NCVkeHUh?=
CP66-MEL NIizNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEezJI5O NW\2eYl{W0GQR1XS
LB771-HNC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyTWM2OD1yLkS3OEBvVQ>? M2DBUnNCVkeHUh?=
DSH1 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv5XXFKSzVyPUCuOFghdk1? NV2wcmw2W0GQR1XS
HUTU-80 NGqxVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\kfYpKSzVyPUCuOVM{KG6P MnP1V2FPT0WU
CESS M4\sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzYcI9sUUN3ME2wMlU{QCCwTR?= NFHq[ZRUSU6JRWK=
NCI-H747 NF3yb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HFemlEPTB;MD61N|khdk1? NXHu[|BNW0GQR1XS
HT-144 M4n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwNUe2JI5O NIe5SpFUSU6JRWK=
COLO-829 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvpcmFKSzVyPUCuOlE1KG6P M{G0[nNCVkeHUh?=
A4-Fuk MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLTVHM5UUN3ME2wMlYzOyCwTR?= NXfJd3Q4W0GQR1XS
GI-ME-N M{WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnwTWM2OD1yLk[zOEBvVQ>? MoXSV2FPT0WU
LB831-BLC NWTYdppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNkSxJI5O MVvTRW5ITVJ?
HOP-62 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TwVWlEPTB;MD62OFchdk1? M2f4SnNCVkeHUh?=
BB49-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Gw[2lEPTB;MD62OVIhdk1? NXP4cVhMW0GQR1XS
D-336MG Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNkW3JI5O NEnvbpVUSU6JRWK=
TK10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNke5JI5O NGXCSoRUSU6JRWK=
Ramos-2G6-4C10 NULMV2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNkmzJI5O M3vXbXNCVkeHUh?=
LB373-MEL-D NX\6dXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD1yLkegcm0> M{nw[XNCVkeHUh?=
SF126 NVLJNlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPNdHFKSzVyPUCuO|AyKG6P Ml;QV2FPT0WU
UACC-257 NFHXVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwN{Ggcm0> NGDwN5RUSU6JRWK=
KINGS-1 M{HXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne1TWM2OD1yLkeyNkBvVQ>? NYjwOHN3W0GQR1XS
LS-513 NHrCd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzRTHhTUUN3ME2wMlc{QSCwTR?= MlvsV2FPT0WU
GI-1 NHLCW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzETWM2OD1yLke2OEBvVQ>? NYDpXGM{W0GQR1XS
ES7 M4HhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnDVndKUUN3ME2wMlc3PiCwTR?= NYDBcXhvW0GQR1XS
LB2241-RCC M33nfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3FTWM2OD1yLkiwOEBvVQ>? NX;nTpprW0GQR1XS
D-263MG NI\Yc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvPfIFKSzVyPUCuPFA4KG6P MlXMV2FPT0WU
SW684 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XjN2lEPTB;MD64NlEhdk1? NVT4d3VmW0GQR1XS
ML-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnrUHBKSzVyPUCuPFIyKG6P NGTUW4hUSU6JRWK=
SK-LMS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrnUHJKSzVyPUCuPFU1KG6P MYrTRW5ITVJ?
TE-5 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwOE[1JI5O MYfTRW5ITVJ?
QIMR-WIL NWjWRYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nlNGlEPTB;MD64PFkhdk1? Ml2zV2FPT0WU
NCI-H1355 NFzvZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjEcow{UUN3ME2wMlg6PSCwTR?= NHnDboZUSU6JRWK=
SNB75 NXq4dGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jGWmlEPTB;MD65NVIhdk1? NHfiVHVUSU6JRWK=
RXF393 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;2VWlEPTB;MD65NVQhdk1? MWPTRW5ITVJ?
IST-MEL1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PN[2lEPTB;MD65NVchdk1? NWn4c5pRW0GQR1XS
SF268 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzXUpBuUUN3ME2wMlkzOyCwTR?= NXvucHlIW0GQR1XS
KALS-1 NYO4foxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonQTWM2OD1yLkmyOUBvVQ>? NHXmZm9USU6JRWK=
HC-1 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPvTWM2OD1yLkm3OUBvVQ>? NIPyb4pUSU6JRWK=
SW872 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK4V5FKSzVyPUCuPVk3KG6P NHrlc2hUSU6JRWK=
PSN1 M13jS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwMEGgcm0> NFHtfYVUSU6JRWK=
TE-1 NXvYfINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwMEOgcm0> MnXvV2FPT0WU
TE-10 NEjoWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy2PFJzUUN3ME2xMlA{KG6P MlzqV2FPT0WU
RKO NIfR[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq5dG1KSzVyPUGuNFYhdk1? MoriV2FPT0WU
LC-2-ad NGfjRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[3RXFKSzVyPUGuNFghdk1? NX7ScVY2W0GQR1XS
SK-MM-2 NEnkeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rYT2lEPTB;MT6wPUBvVQ>? M2PYTXNCVkeHUh?=
VA-ES-BJ MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESyOWNKSzVyPUGuNFkhdk1? NE\wUYNUSU6JRWK=
MZ7-mel NEPXfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKdlBvUUN3ME2xMlA6KG6P MlXlV2FPT0WU
D-392MG NVrxboNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwMTDuUS=> Mn7pV2FPT0WU
CCRF-CEM NWfscI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWTWM2OD1zLkGzJI5O NHTqbIZUSU6JRWK=
EM-2 NXXGR5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v6PWlEPTB;MT6xOkBvVQ>? MVnTRW5ITVJ?
HAL-01 NYHwWZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[3TmlEPTB;MT6xPEBvVQ>? NETMUoxUSU6JRWK=
TE-8 NH32bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PsNmlEPTB;MT6xPUBvVQ>? Mn3SV2FPT0WU
NCI-H1882 M4rSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTRTWM2OD1zLkKgcm0> MXHTRW5ITVJ?
Daudi M13BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rtcmlEPTB;MT6yNkBvVQ>? MXXTRW5ITVJ?
BL-41 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XMU2lEPTB;MT6yOUBvVQ>? NYDM[FViW0GQR1XS
SR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nWcWlEPTB;MT6yOUBvVQ>? MXHTRW5ITVJ?
KM12 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr1PWw2UUN3ME2xMlI4KG6P NEDT[4VUSU6JRWK=
K5 M2TEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnmWFNmUUN3ME2xMlI5KG6P NHPyZ2ZUSU6JRWK=
A3-KAW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkZ4hKSzVyPUGuNlghdk1? MYPTRW5ITVJ?
CMK NI\I[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHCVm54UUN3ME2xMlI6KG6P NIfYSodUSU6JRWK=
Calu-6 M{X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq1dXhtUUN3ME2xMlI6KG6P MkHPV2FPT0WU
IST-SL2 NXjsXXViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDRb5NKSzVyPUGuN|Ehdk1? NYDHOY9pW0GQR1XS
OPM-2 M{XOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rncGlEPTB;MT6zN{BvVQ>? M2P3UnNCVkeHUh?=
DU-4475 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjBSWZIUUN3ME2xMlM3KG6P NFf3OmFUSU6JRWK=
ECC12 M4\3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDTXmlMUUN3ME2xMlM4KG6P M13aUXNCVkeHUh?=
L-540 NUTwbY5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TyS2lEPTB;MT6zO{BvVQ>? MU\TRW5ITVJ?
CAS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XGeWlEPTB;MT6zO{BvVQ>? M2TiSXNCVkeHUh?=
PF-382 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzFU2ZKSzVyPUGuOFchdk1? NXvXOYl7W0GQR1XS
LS-411N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrETWM2OD1zLkWzJI5O M4i5VXNCVkeHUh?=
NCI-H69 M{XTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\UTWM2OD1zLkW0JI5O M2rwVXNCVkeHUh?=
NB12 NUDXSpFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjBRllpUUN3ME2xMlU3KG6P NF\CW3JUSU6JRWK=
HEL MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW0b|ZGUUN3ME2xMlYyKG6P MX3TRW5ITVJ?
GCIY NHPGXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFRm1yUUN3ME2xMlYzKG6P NWW1TmhyW0GQR1XS
EHEB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzBcIZDUUN3ME2xMlY4KG6P MVLTRW5ITVJ?
TGBC1TKB NGf1[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXJTWM2OD1zLkexJI5O NX\rVZJvW0GQR1XS
KURAMOCHI M2\2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPyTWM2OD1zLkeyJI5O MlHTV2FPT0WU
U-266 M1LiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTxTWM2OD1zLke2JI5O NE\xepFUSU6JRWK=
LC4-1 NF;U[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXWOJdKSzVyPUGuO|khdk1? MXzTRW5ITVJ?
NCI-H2126 M1XvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLlcmJbUUN3ME2xMlghdk1? MUnTRW5ITVJ?
NCI-H1092 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:xfm1KSzVyPUGuPEBvVQ>? MXfTRW5ITVJ?
GB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1U2lEPTB;MT64NUBvVQ>? MmXaV2FPT0WU
MV-4-11 NFfPTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\QbJFKSzVyPUGuPFIhdk1? NIH3[ZBUSU6JRWK=
Becker M4fWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwOEOgcm0> NUTTZ4lYW0GQR1XS
MPP-89 M3;vdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwOEmgcm0> NFXHV|VUSU6JRWK=
BE-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i4TmlEPTB;MT65N{BvVQ>? NV;s[YRLW0GQR1XS
697 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjjTWM2OD1zLkm5JI5O M3K0VnNCVkeHUh?=
NKM-1 NUPq[25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPXTWM2OD1{IH7N MUPTRW5ITVJ?
NB13 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\neYJKSzVyPUKgcm0> NX\sWVQ2W0GQR1XS
LS-123 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwMEKgcm0> NX3sSGdKW0GQR1XS
NB17 M2HDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\YT4hKSzVyPUKuNFQhdk1? NFv3PWRUSU6JRWK=
LAN-6 M4\mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli2TWM2OD1{LkC1JI5O Mor2V2FPT0WU
EW-24 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjIUlNKSzVyPUKuNFghdk1? MkXFV2FPT0WU
NOS-1 NVXxcJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XNcmlEPTB;Mj6xNUBvVQ>? Ml72V2FPT0WU
BL-70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PXfWlEPTB;Mj6xNkBvVQ>? Ml3sV2FPT0WU
GT3TKB NXTpUnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmwTWM2OD1{LkGyJI5O MVjTRW5ITVJ?
HH MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r4VGlEPTB;Mj6xN{BvVQ>? MmfDV2FPT0WU
KE-37 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMUOgcm0> M4i5S3NCVkeHUh?=
MOLT-4 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm2bVdKSzVyPUKuNVMhdk1? NWf5d4QxW0GQR1XS
EKVX MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPQeVBYUUN3ME2yMlE1KG6P NUHJV2hZW0GQR1XS
KGN M13jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwMUWgcm0> MYnTRW5ITVJ?
ES4 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHrPHRxUUN3ME2yMlE3KG6P MoHEV2FPT0WU
SJSA-1 NVPGV5RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3tTWM2OD1{LkKxJI5O M2f3XHNCVkeHUh?=
KMOE-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rkVWlEPTB;Mj6yN{BvVQ>? MVzTRW5ITVJ?
NB5 NUXVNFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwMkegcm0> M2jFZXNCVkeHUh?=
BC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5R25KSzVyPUKuN|Ehdk1? NXGzVodGW0GQR1XS
NB10 NWXZbphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzQTWM2OD1{LkOyJI5O NXrJWZFiW0GQR1XS
RPMI-8226 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu3OJlPUUN3ME2yMlM2KG6P MX7TRW5ITVJ?
SCC-3 NVjMbWNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDRSmU3UUN3ME2yMlM4KG6P NVfLb2NRW0GQR1XS
ARH-77 M1HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO4W|hKSzVyPUKuN|ghdk1? NGS5fJdUSU6JRWK=
NCI-H748 NIjsSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOwTIFKSzVyPUKuN|khdk1? MlXXV2FPT0WU
KU812 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5ZWlEPTB;Mj60NkBvVQ>? NYD4OmxpW0GQR1XS
NCI-H64 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vJdmlEPTB;Mj60OEBvVQ>? NYPveZhQW0GQR1XS
NB69 M2rQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLHTWM2OD1{LkS2JI5O NVvE[YpwW0GQR1XS
KNS-81-FD MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwNEigcm0> MV3TRW5ITVJ?
LB1047-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXNOHdbUUN3ME2yMlU4KG6P NV3UeI9vW0GQR1XS
EB-3 NV7xeYVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\qRldKSzVyPUKuOlYhdk1? M3nQT3NCVkeHUh?=
Mo-T NIi5SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTQTWM2OD1{Lke0JI5O MXLTRW5ITVJ?
EW-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW0VZMyUUN3ME2yMlc2KG6P MXvTRW5ITVJ?
CTV-1 NWm2V5NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4POcWlEPTB;Mj64JI5O Mm\EV2FPT0WU
ETK-1 NEDiUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZb4ZbUUN3ME2yMlg1KG6P NYWwd2k5W0GQR1XS
C2BBe1 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jWRWlEPTB;Mj64PUBvVQ>? Mnf4V2FPT0WU
MOLT-16 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:ydHpKSzVyPUKuPFkhdk1? NGfRRYJUSU6JRWK=
SW954 NFHtNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33iV2lEPTB;Mj65JI5O NH3neJlUSU6JRWK=
HT M4XTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISyZ|JKSzVyPUOuNFIhdk1? MorNV2FPT0WU
KARPAS-299 M1W4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PQOGlEPTB;Mz6wOkBvVQ>? MYrTRW5ITVJ?
MONO-MAC-6 NIfLN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwMTDuUS=> NFKwOYFUSU6JRWK=
CGTH-W-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELX[2FKSzVyPUOuNUBvVQ>? NELDPFJUSU6JRWK=
SK-PN-DW MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fZ[mlEPTB;Mz6xOEBvVQ>? NVfS[VZiW0GQR1XS
CW-2 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXXd3BKSzVyPUOuNlEhdk1? MkDPV2FPT0WU
SK-N-DZ NFrSS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO5fJFKSzVyPUOuNlYhdk1? MXnTRW5ITVJ?
NEC8 M{WyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jhT2lEPTB;Mz6zOUBvVQ>? M33wb3NCVkeHUh?=
LB996-RCC MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwNDDuUS=> NITmWW9USU6JRWK=
DB NFLOdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH1S5JKSzVyPUOuOFEhdk1? M4W4RXNCVkeHUh?=
TE-15 M1H0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f0OmlEPTB;Mz60N{BvVQ>? M2q0dXNCVkeHUh?=
COR-L88 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHuTFU6UUN3ME2zMlQ4KG6P NWO2O2M2W0GQR1XS
LAMA-84 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKy[FVwUUN3ME2zMlQ6KG6P M4\vNnNCVkeHUh?=
MEG-01 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDsTWM2OD1|LkS5JI5O M3;aO3NCVkeHUh?=
LOXIMVI M4L6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LvcmlEPTB;Mz61JI5O NYnvenJkW0GQR1XS
RPMI-8402 NFm0O4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K3dWlEPTB;Mz61JI5O M3X4VXNCVkeHUh?=
KARPAS-45 NUjUUZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf5TWM2OD1|LkW0JI5O NFzvfZpUSU6JRWK=
HCC1187 NXy2PVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPGTWM2OD1|LkW0JI5O MVPTRW5ITVJ?
MZ1-PC Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H4bmlEPTB;Mz61OEBvVQ>? MkD5V2FPT0WU
no-11 NXTBVok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\uW3RXUUN3ME2zMlU2KG6P M2nxO3NCVkeHUh?=
EVSA-T NE\0NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvXZmd5UUN3ME2zMlYhdk1? M1:4enNCVkeHUh?=
DJM-1 M2\3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLZOpRqUUN3ME2zMlY{KG6P M4HQ[nNCVkeHUh?=
COLO-684 NIrjcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M331dGlEPTB;Mz62OkBvVQ>? MVnTRW5ITVJ?
NMC-G1 M13BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHhXGNKSzVyPUOuOlghdk1? M4LaPXNCVkeHUh?=
LC-1F MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjQTGxKSzVyPUOuO|Qhdk1? NWLhb297W0GQR1XS
RL95-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfRUG1mUUN3ME2zMlc6KG6P MX;TRW5ITVJ?
COLO-320-HSR M2nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELOVmpKSzVyPUOuPVIhdk1? MWDTRW5ITVJ?
RCC10RGB NFfPeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS4NWNkUUN3ME2zMlk{KG6P NFLvRZpUSU6JRWK=
HD-MY-Z NUTnUmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml24TWM2OD1|LkmzJI5O MVPTRW5ITVJ?
NCI-H2141 NXzSW4piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLTWM2OD12LkC1JI5O NUDhN2sxW0GQR1XS
K-562 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzQTWM2OD12LkGyJI5O NVXldlVCW0GQR1XS
NCI-H1648 NYjtbIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjjcWJKSzVyPUSuNVMhdk1? MVHTRW5ITVJ?
OMC-1 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTRwMUigcm0> NVjs[VY6W0GQR1XS
LB647-SCLC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD12LkKyJI5O M3T3W3NCVkeHUh?=
TE-12 NGmxXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfEUplTUUN3ME20MlI2KG6P NH7pXnJUSU6JRWK=
NOMO-1 NWrDcodNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDsR25KUUN3ME20MlM{KG6P MlTDV2FPT0WU
Raji MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfETWM2OD12LkS2JI5O M3m3THNCVkeHUh?=
NALM-6 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwNEmgcm0> NHjHfFVUSU6JRWK=
HL-60 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnNTWM2OD12Lk[3JI5O NU\Vd2NPW0GQR1XS
IST-SL1 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO0TWM2OD12Lk[4JI5O NY\qTlBJW0GQR1XS
MHH-PREB-1 M164V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7VOHczUUN3ME20Mlg3KG6P M2S3[HNCVkeHUh?=
MHH-NB-11 M3zDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ZTWM2OD12LkmxJI5O MYXTRW5ITVJ?
JiyoyeP-2003 NXq1VZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTVibl2= NH\NZ2ZUSU6JRWK=
SBC-1 NXrGfGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvtfHZKSzVyPUWuNFEhdk1? NXPPZoV1W0GQR1XS
CHP-126 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLDTWM2OD13LkC2JI5O MnvQV2FPT0WU
LU-139 NV74cWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELQVXNKSzVyPUWuNVMhdk1? NFLyNXJUSU6JRWK=
NCI-SNU-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L3WWlEPTB;NT6xO{BvVQ>? M4D0PXNCVkeHUh?=
SW962 M{PUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD3TWM2OD13LkKxJI5O NGf1T4JUSU6JRWK=
EW-1 M3jEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXnNmlvUUN3ME21MlMyKG6P MlrTV2FPT0WU
NCI-H1417 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwNUGgcm0> M3TRRXNCVkeHUh?=
LU-65 NXfHdGFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHSwSmNKSzVyPUWuPFQhdk1? NFyweJFUSU6JRWK=
D-502MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXldHNNUUN3ME22MlM4KG6P NEPFSmlUSU6JRWK=
BC-3 NILybXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS0TmRSUUN3ME22MlYyKG6P MnHRV2FPT0WU
GDM-1 M{eyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfXTWM2OD14Lke3JI5O NFP6fldUSU6JRWK=
NCI-H2196 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwODDuUS=> MljmV2FPT0WU
NB1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;scHRKSzVyPU[uPFghdk1? MkWzV2FPT0WU
NCI-H345 NH22dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnGfnVKSzVyPUeuNkBvVQ>? MlvYV2FPT0WU
SU-DHL-1 NFfhXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK0foFOUUN3ME23MlI1KG6P M2ThWXNCVkeHUh?=
JVM-2 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwMkigcm0> MoLyV2FPT0WU
LU-134-A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fSNmlEPTB;Nz6zPUBvVQ>? Mn7IV2FPT0WU
NCI-H1694 NHLIPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjuRlN7UUN3ME23MlU5KG6P MnXaV2FPT0WU
NCI-SNU-16 M3:2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwNkWgcm0> M1LHeHNCVkeHUh?=
L-363 NXnl[XF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD15Lkegcm0> MnX3V2FPT0WU
KG-1 NXjJVXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjxdm1KSzVyPUeuPVQhdk1? NX3HR3pWW0GQR1XS
MN-60 M3Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiyTZhKSzVyPUiuNVQhdk1? NIK4eVJUSU6JRWK=
NB6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRThwNEigcm0> MVjTRW5ITVJ?
MLMA M3XSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITreFNKSzVyPUiuPFUhdk1? Ml;5V2FPT0WU
ATN-1 M{HN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTXW4tKSzVyPUiuPFkhdk1? M1TqSHNCVkeHUh?=
SK-NEP-1 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G5b2lEPTB;OT6wNUBvVQ>? MmrlV2FPT0WU
DMS-114 M1\kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT2[mtKSzVyPUmuOlIhdk1? MXLTRW5ITVJ?
CTB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5PI9KSzVyPUmuOlchdk1? M4nv[nNCVkeHUh?=
NCI-H2081 NYLE[nJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyLkC5JI5O MnHkV2FPT0WU
ES5 NXTNbJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDpS5NKSzVyPUGwMlM5KG6P NX65Tm04W0GQR1XS
HCC1599 NFO1T|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFzLkmxJI5O M3fB[3NCVkeHUh?=
NCI-H23 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1zMj6xNkBvVQ>? MojXV2FPT0WU
NCI-H1581 NFfFcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF{LkK4JI5O NGPTelhUSU6JRWK=
JVM-3 NILDOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBe|JKSzVyPUGyMlk6KG6P NETFb2RUSU6JRWK=
NCI-SNU-1 M{fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|LkG5JI5O M2rXXHNCVkeHUh?=
NB7 NF;GO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljiTWM2OD1zNT65NkBvVQ>? M1fJV3NCVkeHUh?=
JAR MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DUfWlEPTB;MU[uNVMhdk1? MlnuV2FPT0WU
TGW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zlRmlEPTB;MU[uOFghdk1? NFXGT49USU6JRWK=
U-87-MG M331fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\MTWM2OD1zNj63OkBvVQ>? M3j0TXNCVkeHUh?=
NCI-H1436 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonHTWM2OD1zNz6wNUBvVQ>? M2HEfHNCVkeHUh?=
GOTO NUjidotDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfKPVVKSzVyPUG3MlA3KG6P Mm\MV2FPT0WU
COLO-800 NYDwOZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P4[mlEPTB;MUeuOlQhdk1? NWrQPGpMW0GQR1XS
MFM-223 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF5LkmxJI5O MoW2V2FPT0WU
EW-18 NXjYTmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL4Z2JEUUN3ME2xO{46PiCwTR?= M4DkVXNCVkeHUh?=
NB14 NWfiS2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zP[2lEPTB;MUeuPVghdk1? NIPWdFhUSU6JRWK=
EB2 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF6LkC4JI5O MmOxV2FPT0WU
EoL-1- MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPRTWM2OD1zOD6zNUBvVQ>? M2n5ZnNCVkeHUh?=
NCCIT MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf0TWM2OD1zOD6zOkBvVQ>? NFjqN4VUSU6JRWK=
DG-75 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF6Lk[xJI5O M1zuR3NCVkeHUh?=
HCC2218 NIDUR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF7LkWgcm0> NW\ofJY{W0GQR1XS
TE-6 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvGTWM2OD1{MD6wPEBvVQ>? NWnRO5YzW0GQR1XS
SF539 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHJTWM2OD1{MD62O{BvVQ>? NWXXZ|VSW0GQR1XS
NCI-H446 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJzLkG4JI5O M1j4T3NCVkeHUh?=
IST-MES1 NIH5OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7wUJg4UUN3ME2yNk44PyCwTR?= M4HDO3NCVkeHUh?=
NCI-H82 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ|LkCyJI5O NVX5V2J3W0GQR1XS
HCC2157 NH3nd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ|LkGzJI5O NF71UWlUSU6JRWK=
EW-12 M4[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnNVG04UUN3ME2yN{4yPyCwTR?= NF21SFBUSU6JRWK=
SIMA NULJbZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnrWWpXUUN3ME2yN{4{QCCwTR?= Mm\rV2FPT0WU
DOHH-2 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1npT2lEPTB;MkOuOFUhdk1? MnfpV2FPT0WU
IM-9 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLGbmRxUUN3ME2yN{42PCCwTR?= M4LlWXNCVkeHUh?=
EC-GI-10 M1HRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfjfXhtUUN3ME2yOE4zOyCwTR?= NI\YXGtUSU6JRWK=
HDLM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYeFRKSzVyPUK0MlU1KG6P MWLTRW5ITVJ?
LS-1034 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L0VmlEPTB;MkWuO|Uhdk1? NUDsUVN3W0GQR1XS
REH NV3lb3duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PNN2lEPTB;Mk[uOFEhdk1? MknNV2FPT0WU
LU-165 NX:3fWNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ4LkeyJI5O MWrTRW5ITVJ?
NH-12 M1zmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TEZmlEPTB;MkeuOlchdk1? M2OzVHNCVkeHUh?=
WSU-NHL Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[z[oZKSzVyPUK4MlM6KG6P NGnnNFhUSU6JRWK=
ECC4 NGi5NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\3W4JKSzVyPUK4Mlc6KG6P M4n6cnNCVkeHUh?=
OCI-AML2 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXIOJBKSzVyPUK5MlY6KG6P NGruSpdUSU6JRWK=
EW-3 M3rBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\STpdKSzVyPUOwMlU6KG6P M17LNHNCVkeHUh?=
NCI-H526 NFG0fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN{LkW0JI5O NFvGPIVUSU6JRWK=
NCI-H719 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1eWlEPTB;M{SuN|Ehdk1? M4LMXHNCVkeHUh?=
KARPAS-422 NInkNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWeVlKSzVyPUO1MlA1KG6P NFq1WmFUSU6JRWK=
SK-MEL-1 M3\4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN3LkG3JI5O NHrocJJUSU6JRWK=
ES3 NXi1VFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHQTYxbUUN3ME2zOU4yQSCwTR?= MYLTRW5ITVJ?
UACC-812 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[2TWM2OD1|NT60OEBvVQ>? NYL5ToF1W0GQR1XS
C8166 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TOSWlEPTB;M{WuO{BvVQ>? NUHhUIl6W0GQR1XS
MDA-MB-134-VI M1fIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN3Lki3JI5O NV;vTnZyW0GQR1XS
D-283MED M4LNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jI[mlEPTB;M{euO|khdk1? NVfJVHZ{W0GQR1XS
SHP-77 NUfZ[XI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTN6LkCzJI5O MYDTRW5ITVJ?
NCI-H2227 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv3OVZKSzVyPUSwMlQ6KG6P NYn4dYZLW0GQR1XS
SKM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;BOXBKSzVyPUSyMlY{KG6P NFXn[HhUSU6JRWK=
L-428 NEjjU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR|Lki2JI5O Mn35V2FPT0WU
RPMI-6666 NG\1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPrTWM2OD12NT64PUBvVQ>? NF3QbWNUSU6JRWK=
NCI-H716 NYXGRnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTLWFVmUUN3ME20PE45OSCwTR?= MXjTRW5ITVJ?
DMS-79 NUW2V5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPDUZFKSzVyPUWwMlcyKG6P NHTIfWVUSU6JRWK=
RS4-11 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP3ephmUUN3ME21NE45QCCwTR?= M17ubXNCVkeHUh?=
NCI-H720 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XvTWlEPTB;NUGuNVEhdk1? MnyzV2FPT0WU
MC-CAR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2TGlEPTB;NUGuOVIhdk1? NVizXI5vW0GQR1XS
TALL-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\N[JhMUUN3ME21N{46OSCwTR?= NUXnS3pIW0GQR1XS
NCI-N87 NHnXdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3myWGlEPTB;NUSuNVghdk1? NVzxPIlNW0GQR1XS
P30-OHK M2LhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OxbWlEPTB;NUSuOlEhdk1? MlrKV2FPT0WU
LP-1 NFn0TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\0fplDUUN3ME22NU4zQCCwTR?= Ml\1V2FPT0WU
YT MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrKTWM2OD14MT64JI5O NGSzZ5NUSU6JRWK=
MRK-nu-1 NVyxXWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf6TmpKSzVyPU[xMlgzKG6P MVrTRW5ITVJ?
BT-474 NWXZeJVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXzWYdKSzVyPU[1JI5O MXHTRW5ITVJ?
NCI-H322M NIr6fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ4LkGxJI5O NIXoPXZUSU6JRWK=
NCI-H128 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\OXpVEUUN3ME23OE44PyCwTR?= NIO2bpdUSU6JRWK=
KMS-12-PE NVLoNnFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQSmlEPTB;N{[uNlQhdk1? MXrTRW5ITVJ?
KP-N-YS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnzTWM2OD15Nj63OEBvVQ>? M1z1c3NCVkeHUh?=
ALL-PO MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3dmRKSzVyPUe3MlY3KG6P NEPQSmpUSU6JRWK=
EW-13 NW\LeVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTd5Lke2JI5O NIL2TIlUSU6JRWK=
EW-11 NEO1UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTd6LkWyJI5O M2HYSHNCVkeHUh?=
SK-N-FI NFnGepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[wWmlEPTB;OECuNkBvVQ>? NUTwRoF1W0GQR1XS
CAL-148 NUPkdHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITJR5BKSzVyPUixMlg1KG6P MofZV2FPT0WU
RL NHX5eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULtTYlFUUN3ME24Ok4xQSCwTR?= MYnTRW5ITVJ?
AM-38 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[2NWZKSzVyPUi4MlA5KG6P Ml3VV2FPT0WU
RH-1 M{XRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfXVmxKSzVyPUm5Mlg2KG6P MnXLV2FPT0WU
NCI-H1770 NXu1Rph6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWUlFKSzVyPUGwNk41QSCwTR?= MU\TRW5ITVJ?
SIG-M5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFyNT6wOkBvVQ>? NVXhemdiW0GQR1XS
GR-ST NInvbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjIb3JKSzVyPUGxN{4{PCCwTR?= NF6xSoNUSU6JRWK=
ST486 M37B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFzND6wOkBvVQ>? M1zwSnNCVkeHUh?=
NCI-H1650 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4TWM2OD1zMUWuNlkhdk1? NUnHOmpiW0GQR1XS
MHH-CALL-2 NWXtW3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfHV4hKSzVyPUGxOU44KG6P MYDTRW5ITVJ?
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v6bWlEPTB;MUKyMlcyKG6P MY\TRW5ITVJ?
MC116 NGS5RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L4VGlEPTB;MUS4Mlg2KG6P M3Ppe3NCVkeHUh?=
NCI-H524 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jPTWlEPTB;MUW5MlEhdk1? MlLWV2FPT0WU
SCLC-21H M33MdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4T3NKSzVyPUG1PU41OSCwTR?= M1HzVnNCVkeHUh?=
NCI-H1304 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrMc4FCUUN3ME2xOlkvOjFibl2= MnPJV2FPT0WU
NCI-H510A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjmRVBKSzVyPUG4OU4{PyCwTR?= NHLrUYlUSU6JRWK=
NCI-H209 NFzmSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nJfGlEPTB;MUm2MlUzKG6P MUPTRW5ITVJ?
KM-H2 NEXmW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfhNJFKSzVyPUG5O{4xPSCwTR?= NVvHZYZCW0GQR1XS
NCI-H1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\mTWM2OD1{MUCuNVMhdk1? MlXqV2FPT0WU
NCI-H1155 M2HUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ|MD6zNkBvVQ>? MXTTRW5ITVJ?
COR-L279 NWf6[VVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ3Mj6xO{BvVQ>? Mn2xV2FPT0WU
NCI-H1299 NF7y[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnnOZo4UUN3ME2yOlEvPzFibl2= M3T6TXNCVkeHUh?=
EW-22 NWrDSXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIex[4lKSzVyPUK2N{44PSCwTR?= MnTZV2FPT0WU
SK-MEL-2 NHOyPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD1{OEGuPUBvVQ>? M1jYNHNCVkeHUh?=
KASUMI-1 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wT2lEPTB;MkizMlA2KG6P NHfJN4hUSU6JRWK=
NCI-H187 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHrcnNGUUN3ME2yPFcvODhibl2= M1L5OHNCVkeHUh?=
NCI-H2171 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwV2lEPTB;Mki4MlkzKG6P Mkm4V2FPT0WU
LNCaP-Clone-FGC NH:2cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ7NT6yOkBvVQ>? MoK0V2FPT0WU
NCI-H1522 NIj1U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrDXHFoUUN3ME2zNFcvODVibl2= NGLQW3RUSU6JRWK=
SCH NF7oZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHxWlBKSzVyPUOyNk4zOiCwTR?= NVj4Uop{W0GQR1XS
THP-1 M1naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGwTWM2OD1|MkKuOkBvVQ>? NUHYbJlNW0GQR1XS
SNU-C1 NH;l[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN4Mj6wPUBvVQ>? M3;RcnNCVkeHUh?=
CA46 M2\C[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzOTWM2OD1|N{OuOlMhdk1? M{nKZ3NCVkeHUh?=
NCI-H1963 M4LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN6Nj6xPUBvVQ>? M{TSO3NCVkeHUh?=
DEL NH3SWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\yZldKSzVyPUO5NU4zPyCwTR?= M3jyc3NCVkeHUh?=
TUR M4DQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfmUYNvUUN3ME2zPVYvPjFibl2= NFWxfo9USU6JRWK=
NCI-H226 NHGxcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRyMz6yN{BvVQ>? NYLQRoJpW0GQR1XS
COLO-668 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjwTWM2OD12MEOuOVchdk1? NXewXVhMW0GQR1XS
CPC-N NGnRNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRyMz63O{BvVQ>? M{D0SHNCVkeHUh?=
NCI-H889 Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrDTGdKSzVyPUS2NU46OiCwTR?= Mn;DV2FPT0WU
J-RT3-T3-5 NV\nfppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTV|Mj61O{BvVQ>? M362eHNCVkeHUh?=
MSTO-211H NIrsTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPuTWM2OD13N{SuNlYhdk1? MVfTRW5ITVJ?
SCC-15 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPKTWM2OD14NkeuOFchdk1? MnGwV2FPT0WU
SUP-T1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD14OE[uNFQhdk1? NV3pdHZ2W0GQR1XS
DMS-153 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf1VG5KSzVyPUe0Ok45OyCwTR?= NIDyc3dUSU6JRWK=
MS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT5TWM2OD15NUmuOFIhdk1? MoG3V2FPT0WU
TC-YIK NWPrOZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\BUGlEPTB;N{ixMlAyKG6P NYmxSGFPW0GQR1XS
RPMI-8866 M4f4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFyME[uNlgh|ryP NVjCSVREW0GQR1XS
KY821 NEXLPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHjU5RVUUN3ME2xNFM3NjB2IN88US=> MWjTRW5ITVJ?
P31-FUJ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPzTWM2OD1zMUGyMlc2KM7:TR?= M{jpeHNCVkeHUh?=
COLO-824 NFr0VWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpd45TUUN3ME2xNlYyNjd6IN88US=> MmDDV2FPT0WU
U-698-M MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfqdWZ1UUN3ME2yNlYzNjF3IN88US=> NVrXUmVjW0GQR1XS
TE-441-T NWjQeoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXzN|BKSzVyPUK1NlEvPyEQvF2= MVfTRW5ITVJ?
IMR-5 NVnyOZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrOTWM2OD1|NEC5MlYzKM7:TR?= NGLWbFRUSU6JRWK=
NCI-H1838 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRzOE[uN|Ih|ryP NXPT[W1QW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID